Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07390110 · ClinicalTrials.gov registry record

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

A clinical trial of Heart Failure and Type 2 Diabetes, sponsored by Brigham and Women's Hospital.

Active
Registry status
25,664
Enrollment target
1
Study location

NCT07390110 is a study of Heart Failure and Type 2 Diabetes that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 25,664 participants, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1194% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07390110, a study of Heart Failure and Type 2 Diabetes, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
25,664 participants
Enrollment target
1
Study location

Study Summary

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Interventions

  • DRUG Sitagliptin
  • DRUG Oral semaglutide

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 25,664 participants
Start Date 2026-01-24
Est. Completion 2026-05-11

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT07390110

The ClinicalTrials.gov registry entry for NCT07390110 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 25,664 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,984-participant average among 397 other Heart Failure trials with a reported enrollment target (1194% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Sitagliptin is the first listed.

NCT07390110 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07390110 about?

NCT07390110 is a clinical study titled "Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...

What is the current status of trial NCT07390110?

This trial is currently active not recruiting. The enrollment target is 25,664 participants. The study started on 2026-01-24. Estimated completion is 2026-05-11.

What conditions does trial NCT07390110 study?

This clinical trial studies the following conditions: Heart Failure, Type 2 Diabetes.

What interventions are being tested in trial NCT07390110?

The interventions under investigation include: Sitagliptin (DRUG), Oral semaglutide (DRUG).

Who is sponsoring clinical trial NCT07390110?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07390110 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.